1501.1: A Phase 1, open-label study of BI 770371 (SIRPα antagonist) with or without ezabenlimab (PD-1 inhibitor) in patients with advanced solid tumors
NCT05327946. https://clinicaltrials.gov/ct2/show/NCT05327946. Accessed September 2023.
NCT05327946. https://clinicaltrials.gov/ct2/show/NCT05327946. Accessed September 2023.